行情

RARE

RARE

Ultragenyx药业
NASDAQ

实时行情|Nasdaq Last Sale

54.81
-1.55
-2.75%
交易中 13:10 01/28 EST
开盘
56.89
昨收
56.36
最高
58.00
最低
54.81
成交量
17.93万
成交额
--
52周最高
74.50
52周最低
35.41
市值
31.66亿
市盈率(TTM)
-7.5800
分时
5日
1月
3月
1年
5年

分析师评级

19位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

RARE 新闻

  • 强生称正在研发新型冠状病毒防疫疫苗
  • 新浪财经.53分钟前
  • 里士满联储1月制造业指数升至2018年以来的最高水平
  • 新浪财经.1小时前
  • 美国1月消费者信心指数涨幅超预期 升至5个月来高点
  • 新浪财经.1小时前
  • 疫情掀起央行政策预期调整 欧洲出现大举降息押注
  • 新浪财经.1小时前

更多

所属板块

生物技术和医学研究
+1.13%
制药与医学研究
+0.50%

热门股票

名称
价格
涨跌幅

RARE 简况

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.
展开

Webull提供Ultragenyx Pharmaceutical Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。